
Variantyx: A precision medicine firm using whole genome sequencing for rare genetic disorder diagnosis and oncology treatment optimization.
Founded with a mission to revolutionize precision medicine, Variantyx focuses on providing advanced diagnostic solutions for rare genetic disorders, reproductive genetics, and oncology treatment optimization. Utilizing whole genome sequencing, Variantyx offers comprehensive testing that identifies major genetic changes from a single sample. This empowers patients and healthcare providers with critical information to expedite diagnosis, optimize treatments, and improve overall patient outcomes.
Notable figures in the company include experts in genomics and precision medicine, with significant backing from investors committed to advancing healthcare technology. Variantyx has achieved key milestones in the field of genetic testing, including the development of a unique testing platform that integrates comprehensive analyses for various medical needs. Its impact is profound, offering rapid and accurate diagnostic solutions that significantly enhance patient care and treatment efficacy.

Variant Bio
variantbio.com

Genome Insight

Invitae
invitae.com

Genomenon
genomenon.com

Inform Genomics
informgenomics.com

Nest Genomics
nestgenomics.com

Full Genomes
fullgenomes.com

Sequegenics
sequegenics.com

Geneticure
geneticure.com

Personal Genome Diagnostics
personalgenome.com

GeneDx Holdings
genedx.com

GenomOncology
genomoncology.com

23andMe
23andme.com

My Gene Counsel
mygenecounsel.com

Vyant Bio
Companies similar to Variantyx include Variant Bio, Genome Insight, Invitae and Genomenon.
Variantyx was founded in 2014.
Variantyx's headquarters is located in Framingham, MA, US.
As of Oct 18, 2023, Variantyx has raised a total of $100.5M (USD).
Variantyx has 166 employees as of Feb 4, 2024.